扎嘎齐格大学伊维菌素随机对照研究结果证实PI假设：抗COVID-19的药物有效
扎嘎兹格大学的主要投资者Waheed Shouman博士，
最近完成了一项随机，开放标签，干预性试验，名为
“使用伊维菌素作为COVID-19患者无症状家庭亲密接触中的预防选择。”
该研究针对340名参与者，于8月下旬完成。
这包括总共304名参与者，伊维菌素组203名参与者和对照组101名。
这项调查的目的
目的是确定伊维菌素是否可以作为预防药物，并包括为期14天的随访期，涉及诊断COVID-19症状。
调查结果表明
伊维菌素具有统计学上的显着益处
as a prophylaxis to prevent symptomatic COVID-19 infection in individuals that have been exposed to close family members diagnosed with COVID-19.
This study confirms the author’s hypothesis
that ivermectin in fact possesses an antiviral effect and demonstrates efficacy in preventing the development of symptomatic infection for those individuals that have come in close contact to family members diagnosed with COVID-19.
Importantly, these findings haven’t been peer reviewed nor published in any medical journals.
The study wasn’t’ blinded, the sample size wasn’t that large, etc.
Moreover, the study was conducted in Egypt and hence any findings aren’t necessarily relevant for other food and drug jurisdictions,
such as those in
the United States (FDA),
European Union (EMA), and
the UK (MHRA) etc.